PulseSmartNCT06272981
A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
- Notable Results posted: Nov 17, 2026
- Notable: the plan changed
Endpoints
Primary
Number of Participants With Primary Adverse Events (PAEs)
Timeframe: Up to 12 Months post ablation procedure on Day 0
Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes
Timeframe: From Day 91 up to Day 365 post ablation procedure on Day 0
Secondary (1)
Change From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12
Arms and interventions
Pulsed Field (PF)/Radiofrequency (RF) Ablation SystemExperimental
Participants with drug refractory symptomatic PAF who are candidates for atrial fibrillation ablation uses PF and RF energy to produce targeted intracardiac lesions for the treatment of atrial fibrillation.
Devices: Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation
Sites
7 sites in 2 countries
Canada 4, Australia 3